2. Signaling Pathways
  3. Epigenetics
  4. METTL3

METTL3

Methyltransferase-like 3

 

METTL3 Related Products (17):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-134836
    STM2457
    		Inhibitor 99.86%
    STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC50 of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).
    STM2457
  • HY-156677
    STC-15
    		Inhibitor 99.85%
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases.
    STC-15
  • HY-115717
    UZH2
    		Inhibitor 98.73%
    UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM.
    UZH2
  • HY-162080
    METTL1-WDR4-IN-1
    		Inhibitor 98.87%
    METTL1-WDR4-IN-1 (1) is a METTL1-WDR4 inhibitor, with an IC50 of 144 μM.
    METTL1-WDR4-IN-1
  • HY-153625
    STM2120
    		Inhibitor 99.92%
    STM2120 is a METTL3-METTL14 inhibitor with an IC50 of 64.5 μM.
    STM2120
  • HY-P10387A
    RSM3 TFA
    		Inhibitor
    RSM3 TFA, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 TFA inhibits tumor growth while induces cell apoptosis. RSM3 TFA can be used for study of cancer.
    RSM3 TFA
  • HY-158403
    METTL3-IN-7
    		Inhibitor
    METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research.
    METTL3-IN-7
  • HY-P10387
    RSM3
    		Inhibitor
    RSM3, a stapled peptide, is a METTL3-METTL14 inhibitor with an Kd of 3.10 μM. RSM3 inhibits tumor growth while induces cell apoptosis. RSM3 can be used for study of cancer.
    RSM3
  • HY-134673B
    UZH1b
    		Inhibitor 99.75%
    UZH1b is an enantiomer of UZH1a (a METTL3 inhibitor). UZH1b is essentially inactive for METTL3 (IC50=28 µM).
    UZH1b
  • HY-148467
    METTL3-IN-1
    		Inhibitor
    METTL3-IN-1 (compound 23) is a polyheterocyclic compound, acts as METTL3 inhibitor.
    METTL3-IN-1
  • HY-148468
    METTL3-IN-2
    		Inhibitor
    METTL3-IN-2 (compound 28) is a METTL3 inhibitor with an IC50 value of 6.1 nM. METTL3-IN-2 inhibits cell proliferation of Caov3 cancer cells.
    METTL3-IN-2
  • HY-148469
    METTL3-IN-3
    		Inhibitor
    METTL3-IN-3 (compound 11) is a polyheterocyclic compound, acts as METTL3 inhibitor.
    METTL3-IN-3
  • HY-158404
    METTL3-IN-8
    		Inhibitor
    METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research.
    METTL3-IN-8
  • HY-156759
    METTL3-IN-5
    		Inhibitor
    METTL3-IN-5 (Compound 13) is a METTL3 inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC50 less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC50 >30 μM). METTL3-IN-5 can be used for AML research.
    METTL3-IN-5
  • HY-159604
    METTL3-IN-9
    		Inhibitor
    METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like METTL3, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells.
    METTL3-IN-9
  • HY-154997
    7OQL
    		Inhibitor
    7OQL (compound 54) is a selective METTL3 inhibitor (IC50=0.054 µM). 7OQL has the potential to be used in the study of cancer.
    7OQL
  • HY-162930
    PROTAC METTL3 degrader 1
    		Degrader
    PROTAC METTL3 degrader 1 (Compound KH12) is a VHL-based PROTAC METTL3 degrader (DC50: 220 nM in MOLM-13 cells). PROTAC METTL3 degrader 1 inhibits METTL3/14 complex with an IC50 value of 341 nM. PROTAC METTL3 degrader 1 has anti-proliferative activities against AML cells. Black: Linker (HY-ER002); Red: METTL3 ligand (HY-115717); Blue: VHL ligand (HY-120217).
    PROTAC METTL3 degrader 1